Inhibitor Therapeutics, Inc.
itraconazole
Basal Cell Carcinoma Nevus Syndrome (BCCNS)
Resolved
53days ago
Phase 3 readout · May 15, 2026
What's at stake
Phase 3 trial results for itraconazole in Basal Cell Carcinoma Nevus Syndrome (BCCNS) are due May 15, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“The Company expects to receive top-line comparative PK and relative bioavailability results in advance of the full Clinical Study Report, which will follow completion of the final study documentation.”